Luft, Alexander

Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer

Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 3,617

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2019) · The Lancet

Lung Cancer Research StudiesCancer Immunotherapy and Biomarkers

Cited by 2,298

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Rudin, C. M., Awad, M. M., Navarro, A., Gottfried, M., Peters, S., Csőszi, T., Cheema, P. K., Rodriguez-Abreu, D., Wollner, M., Yang, J. C.-H., et al. (2020) · Journal of Clinical Oncology

Lung Cancer Research StudiesLung Cancer Treatments and Mutations

Cited by 760

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial

Rizvi, N. A., Cho, B. C., Reinmuth, N., Lee, K. H., Luft, A., Ahn, M.-J., van den Heuvel, M. M., Cobo, M., Vicente, D., Smolin, A., et al. (2020) · JAMA Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 623

Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study

Johnson, M. L., Cho, B. C., Luft, A., Alatorre-Alexander, J., Geater, S. L., Laktionov, K., Kim, S.-W., Ursol, G., Hussein, M., Lim, F. L., et al. (2023) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 463

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Wu, Y.-L., Lu, S., Cheng, Y., Zhou, C., Wang, J., Mok, T., Zhang, L., Tu, H.-Y., Wu, L., Feng, J., et al. (2019) · Journal of Thoracic Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 357